Production and evaluation of a new set of recombinant antigens for the serological diagnosis of human cysticercosis - Institut Pasteur de Côte d'Ivoire
Article Dans Une Revue Experimental Parasitology Année : 2024

Production and evaluation of a new set of recombinant antigens for the serological diagnosis of human cysticercosis

Résumé

Human cysticercosis caused by Taenia soliun (T. soliun) is endemic in certain areas of Latin America, Asia and Sub-Saharan Africa. Neurocysticercosis (NCC) is mainly diagnosed by neuroimaging, which, in most cases, is unavailable in endemic areas. Due to their high sensitivity and specificity, serological tests such as enzyme-linked immunosorbent assay (ELISA) and Western blot (WB) based on the glycosylated fraction of the cyst CS50 are widely used for the detection of the anti-cysticercus IgG antibodies despite their significant cost and the need of cysticercus material. Given their cost-effectivess and simplicity, immunoassays based on recombinant proteins could provide new alternatives for human cysticercosis diagnosis: such tests would be aimed at screening those people living in remote areas who need further examination. To date, however, no test using recombinant antigens is commercially available. Herein, five recombinant proteins (R14, R18, R93.1, R914.1, and R915.2) were produced, three of which (R93.1, R914.1, and R915.2) were newly identified from the cyst fluid. Evaluation of the diagnostic performance of these recombinant antigens by ELISA was done using sera from 200 epileptic and non-epileptic individuals in comparison with the WB-CS50 as the reference serological method. Recombinant proteins-based ELISA showed a level of diagnostic performance that is inferior than the reference serological method, but similar to that of the native antigen ELISA for human cysticercosis (commonly used for screening). Further optimization of expression conditions is still needed in order to improve proteins solubility and enhance diagnostic performance for human cysticercosis detection. However, this preliminary evaluation of the recombinant antigens has shown their potential valuable use for screening cysticercosis in patients with epilepsy attending dispensaries in remote areas. Future studies should be conducted to evaluate our recombinant antigens in a large group of patients with different stages of NCC, and in correlation with imaging findings.

Domaines

Parasitologie
Fichier principal
Vignette du fichier
jihen_1-s2.0-S0014489424001061-main.pdf (2.06 Mo) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

pasteur-04664722 , version 1 (30-07-2024)

Licence

Identifiants

Citer

Jihen Melki, Thierry-Borel N'Dri Kouadio, Mireille Nowakowski, Zara Razafiarimanga, Man-Koumba Soumahoro, et al.. Production and evaluation of a new set of recombinant antigens for the serological diagnosis of human cysticercosis. Experimental Parasitology, 2024, 263-264, pp.108803. ⟨10.1016/j.exppara.2024.108803⟩. ⟨pasteur-04664722⟩
22 Consultations
8 Téléchargements

Altmetric

Partager

More